Subject: Participation in survey “Understanding the Real World Practice of Nano-paclitaxel and Perception of Paclitaxel injection concentrate for nanodispersion vs Other Nano-paclitaxel in India”
Paclitaxel is widely used for the treatment of solid tumors; however, the solvent used in the conventional formulation of solvent-based (sb)-paclitaxel, polyoxyethylated castor oil (Cremophor), is associated with severe, sometimes fatal hypersensitivity reactions. To reduce the risk of hypersensitivity reactions with sb-paclitaxel, patients are routinely pretreated with corticosteroids and antihistamines. Furthermore, some studies have shown that Cremophor can entrap paclitaxel in solvent micelles, making the drug less available to enter tumors, thereby limiting its clinical efficacy.
Nab-paclitaxel is a solvent-free albumin-bound form of paclitaxel. Compared with sb-paclitaxel, nab-paclitaxel has several advantages, including the ability to deliver significantly higher doses of paclitaxel over a shorter infusion time (30 minutes vs 3 hours for sb-paclitaxel) and the elimination of the need for pre-medications to prevent hypersensitivity reactions. Other advantages of nab-paclitaxel over sb-paclitaxel include enhanced transport of paclitaxel across endothelial cells and greater delivery of paclitaxel to tumors. Because nab-paclitaxel is formulated with albumin, it is postulated that the drug uses endogenous albumin transport pathways, including receptor-mediated transcytosis, to cross endothelial cell monolayers and enter tumors.
Paclitaxel injection concentrate for nanodispersion (PICN) is an alternative solvent-free formulation of paclitaxel. PICN is a polyoxyethylated castor oil- and albumin free self-assembly nanoparticle formulation of paclitaxel (100–150 nm) stabilized with a polymer (polyvinylpyrrolidone) and lipid (cholesteryl sulfate and caprylic acid) using Nanotecton technology. Unlike, nab-paclitaxel, which utilizes albumin of biological origin, PICN makes use of polymer and lipid mixtures.
There is limited data available on the preference and rationale for selection of different nano-paclitaxel formulation in the management of solid tumors.
Therefore, this multicentric survey is designed to understand the management of solid tumors and place of bevetex (PICN) in solid tumors management in India.
If you agree to participate, you will be required to respond to questions of the enclosed questionnaire. We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this survey. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})